ReviewDiagnostics (Basel, Switzerland)2023
Non-Contrast and Contrast-Enhanced Cardiac Computed Tomography Imaging in the Diagnostic and Prognostic Evaluation of Coronary Artery Disease.
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- The Diagnostic and Prognostic Impact of Cardiovascular Magnetic Resonance in Ischemic Heart Disease: A Systematic Review.Journal of clinical medicine · 2026Review
- Association Between Coronary Artery Calcium Score and Right Ventricular Dysfunction: Insights from Combined Echocardiographic and CT Assessment.Journal of clinical medicine · 2026Article
- The Evolving Role of Coronary Artery Imaging in Assessing Cardiovascular Risk from Lipoprotein(a).Current atherosclerosis reports · 2026Review
- Targeting perivascular adipose tissue in vascular aging: innovative translational strategies for disease prevention and monitoring.Apoptosis : an international journal on programmed cell death · 2026Review
- A fully automated explainable predictive model for diagnosing pre-capillary and post-capillary pulmonary hypertension on routine unenhanced CT: results from the ASPIRE registry.European heart journal. Digital health · 2026Article
- A Comprehensive Review of the Manifestation of Cardiovascular Diseases in HIV Patients.Cureus · 2025Review
- Lung imaging methods: indications, strengths and limitations.Breathe (Sheffield, England) · 2024Review
- The Role of Epicardial Adipose Tissue in Acute Coronary Syndromes, Post-Infarct Remodeling and Cardiac Regeneration.International journal of molecular sciences · 2024Review
- Imaging biomarkers in cardiac CT: moving beyond simple coronary anatomical assessment.La Radiologia medica · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent decades, cardiac computed tomography (CT) has emerged as a powerful non-invasive tool for risk stratification, as well as the detection and characterization of coronary artery disease (CAD), which remains the main cause of morbidity and mortality in the world. Advances in technology have favored the increasing use of cardiac CT by allowing better performance with lower radiation doses. Coronary artery calcium, as assessed by non-contrast CT, is considered to be the best marker of subclinical atherosclerosis, and its use is recommended for the refinement of risk assessment in low-to-intermediate risk individuals. In addition, coronary CT angiography (CCTA) has become a gate-keeper to invasive coronary angiography (ICA) and revascularization in patients with acute chest pain by allowing the assessment not only of the extent of lumen stenosis, but also of its hemodynamic significance if combined with the measurement of fractional flow reserve or perfusion imaging. Moreover, CCTA provides a unique incremental value over functional testing and ICA by imaging the vessel wall, thus allowing the assessment of plaque burden, composition, and instability features, in addition to perivascular adipose tissue attenuation, which is a marker of vascular inflammation. There exists the potential to identify the non-obstructive lesions at high risk of progression to plaque rupture by combining all of these measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.